Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HOTH Hoth Therapeutics	$1.34 +3.1%	$0.97	$0.58 ▼ $3.80	$17.70M	0.55	3.69 million shs	2.61 million shs
SKYE Skye Bioscience	$2.14 +3.4%	$2.13	$1.14 ▼ $9.73	$66.30M	1.69	365,298 shs	99,900 shs
SPRO Spero Therapeutics	$2.94 +1.4%	$1.36	$0.51 ▼ $3.06	$164.38M	1.31	1.16 million shs	1.84 million shs
TNYA Tenaya Therapeutics	$0.58 +0.8%	$0.49	$0.36 ▼ $4.06	$94.10M	2.91	2.62 million shs	1.52 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HOTH Hoth Therapeutics	0.00%	-5.63%	+58.43%	+24.07%	+47.25%
SKYE Skye Bioscience	0.00%	-2.68%	+8.63%	-5.52%	-77.50%
SPRO Spero Therapeutics	0.00%	+1.73%	+332.23%	+257.58%	+131.50%
TNYA Tenaya Therapeutics	0.00%	-3.71%	+21.51%	-9.13%	-81.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HOTH Hoth Therapeutics	3.2287 of 5 stars	3.6	5.0	0.0	2.8	0.8	0.6
SKYE Skye Bioscience	2.3391 of 5 stars	3.5	2.0	0.0	3.8	0.0	0.6
SPRO Spero Therapeutics	3.7146 of 5 stars	3.3	2.0	4.7	2.6	0.0	0.6
TNYA Tenaya Therapeutics	3.4152 of 5 stars	3.5	3.0	0.0	1.4	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HOTH Hoth Therapeutics	3.25	Buy	$4.00	198.51% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	675.70% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	70.07% Upside
TNYA Tenaya Therapeutics	3.00	Buy	$6.25	980.38% Upside

Current Analyst Ratings Breakdown

Latest HOTH, SKYE, SPRO, and TNYA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/9/2025	TNYA Tenaya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
4/25/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/15/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/31/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/31/2025	TNYA Tenaya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/21/2025	SKYE Skye Bioscience	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
3/21/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A
SPRO Spero Therapeutics	$47.98M	3.43	N/A	N/A	$0.85 per share	3.46
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	$1.07 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HOTH Hoth Therapeutics	-$8.19M	-$1.14	N/A	N/A	N/A	N/A	-109.18%	-100.22%	8/8/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A
SPRO Spero Therapeutics	-$68.57M	-$1.28	N/A	N/A	N/A	-156.48%	-123.50%	-58.96%	8/4/2025 (Estimated)
TNYA Tenaya Therapeutics	-$111.13M	-$1.16	N/A	N/A	N/A	N/A	-92.20%	-74.53%	8/14/2025 (Estimated)

Latest HOTH, SKYE, SPRO, and TNYA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	SPRO Spero Therapeutics	-$0.55	-$0.25	+$0.30	-$0.25	$11.00 million	$5.87 million
5/12/2025	Q1 2025	HOTH Hoth Therapeutics	-$0.34	-$0.27	+$0.07	-$0.27	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
5/7/2025	Q1 2025	TNYA Tenaya Therapeutics	-$0.18	-$0.24	-$0.06	-$0.24	N/A	N/A
3/27/2025	Q4 2024	HOTH Hoth Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	N/A	N/A
3/27/2025	Q4 2024	SPRO Spero Therapeutics	-$0.35	-$0.38	-$0.03	-$0.38	$12.40 million	$15.04 million
3/20/2025	Q4 2024	SKYE Skye Bioscience	-$0.30	-$0.24	+$0.06	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TNYA Tenaya Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HOTH Hoth Therapeutics	N/A	15.09	15.08
SKYE Skye Bioscience	N/A	11.85	11.85
SPRO Spero Therapeutics	N/A	2.56	2.56
TNYA Tenaya Therapeutics	N/A	6.68	6.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HOTH Hoth Therapeutics	7.08%
SKYE Skye Bioscience	21.09%
SPRO Spero Therapeutics	25.60%
TNYA Tenaya Therapeutics	90.54%

Insider Ownership

Company	Insider Ownership
HOTH Hoth Therapeutics	10.56%
SKYE Skye Bioscience	4.50%
SPRO Spero Therapeutics	5.50%
TNYA Tenaya Therapeutics	48.65%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HOTH Hoth Therapeutics	4	13.21 million	11.81 million	Not Optionable
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable
SPRO Spero Therapeutics	150	55.91 million	52.84 million	Optionable
TNYA Tenaya Therapeutics	110	162.67 million	83.53 million	Optionable

HOTH, SKYE, SPRO, and TNYA Headlines

Recent News About These Companies

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Rating of "Buy" by Analysts

June 12, 2025 | marketbeat.com

Head-To-Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) versus Alpha Cognition (NASDAQ:ACOG)

June 12, 2025 | americanbankingnews.com

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Sees Large Growth in Short Interest

June 2, 2025 | marketbeat.com

Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 16, 2025 | finanznachrichten.de

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

May 15, 2025 | globenewswire.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 5.10%

May 15, 2025 | aaii.com

Tenaya Therapeutics to Present Five Abstracts on Innovative Heart Disease Gene Therapies at ASGCT 2025 Annual Meeting

May 15, 2025 | nasdaq.com

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Stevanato Group (STVN) and Tenaya Therapeutics (TNYA)

May 11, 2025 | theglobeandmail.com

We're A Little Worried About Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Rate

May 10, 2025 | finance.yahoo.com

Tenaya Therapeutics Reports Q1 2025 Financial Results

May 8, 2025 | tipranks.com

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025 | finance.yahoo.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 5.03%

May 2, 2025 | aaii.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 6.21%

April 30, 2025 | aaii.com

H.C. Wainwright maintains Buy on Tenaya Therapeutics stock

April 26, 2025 | investing.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Up 6.36%

April 26, 2025 | aaii.com

Tenaya announces interim data from ongoing RIDGE study

April 25, 2025 | markets.businessinsider.com

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

April 24, 2025 | globenewswire.com

Tenaya Slashes a Third of Workforce to Fund Development of Cardio Gene Therapies

April 1, 2025 | biospace.com

Why Tenaya Therapeutics, Inc.’s (TNYA) Stock Is Down 11.06%

April 1, 2025 | aaii.com

Tenaya data further builds TN-201 profile, says H.C. Wainwright

April 1, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH, SKYE, SPRO, and TNYA Company Descriptions

Hoth Therapeutics NASDAQ:HOTH

$1.34 +0.04 (+3.08%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.33 -0.01 (-0.75%)

As of 06/18/2025 07:59 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Skye Bioscience NASDAQ:SKYE

$2.14 +0.07 (+3.38%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.08 -0.06 (-3.04%)

As of 06/18/2025 07:24 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Spero Therapeutics NASDAQ:SPRO

$2.94 +0.04 (+1.38%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.92 -0.02 (-0.68%)

As of 06/18/2025 07:59 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Tenaya Therapeutics NASDAQ:TNYA

$0.58 +0.00 (+0.78%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$0.57 0.00 (-0.61%)

As of 06/18/2025 07:29 PM Eastern

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time